Review broad metastatic prostate-cancer prognostic context from disease setting, metastatic burden, PSA, grade group, performance status, and key labs in a simplified educational worksheet.
Metastatic prostate cancer covers a broad range of disease states, from newly diagnosed hormone-sensitive disease to later castration-resistant disease after multiple lines of therapy. Prognosis varies widely with metastatic burden, tumor biology, performance status, laboratory profile, and response to treatment.
This page combines several commonly discussed prognostic features — ECOG status, PSA, Gleason or grade-group pattern, disease extent, and selected laboratory values — into a simplified worksheet. It uses familiar trial concepts such as CHAARTED disease volume to help organize those factors, but it does not reproduce a single validated survival model.
The output should therefore be read as broad prognosis context only. It is meant to help users summarize the case before an oncology discussion, not to replace specialist review, imaging, genomic workup, or formal treatment planning.
Metastatic prostate-cancer prognosis depends on disease burden, biology, performance status, treatment setting, and many factors this page cannot fully capture. This worksheet is most useful when it helps organize those visible factors before a specialist discussion.
Site-defined composite worksheet: - ECOG status, PSA, grade-group pattern, metastatic extent, and selected laboratory abnormalities each add weighted points - Disease setting adjusts the final band so hormone-sensitive and later-line castration-resistant settings are not treated as equivalent - CHAARTED-style high-volume disease is used as contextual framing, not as a complete prognosis model
Result: Intermediate worksheet band, median-survival context ~42 months, 2-year survival context ~70%
A newly diagnosed mCSPC case with ECOG 1, Gleason 4+3, high-volume bone disease, and PSA 45 lands in the worksheet’s intermediate band. The survival numbers are broad context estimates only, not an individualized prediction.
This page pulls together several prognostic features that commonly appear in metastatic prostate-cancer discussions: disease setting, ECOG status, PSA, grade group, metastatic burden, and selected laboratory abnormalities. It is meant to summarize those features in one place, not to replace formal prognostic models or multidisciplinary review.
Trial frameworks such as CHAARTED and LATITUDE remain useful because they describe broad high-burden and lower-burden disease patterns that track with outcomes and treatment intensity. They are helpful anchors for interpretation, but they are not the whole prognosis story by themselves.
Modern prognosis depends on more than the variables on this page. Genomic findings, imaging response, visceral disease pattern, treatment history, symptoms, castration status, and access to newer therapies all matter. That is why the output is presented as worksheet context rather than as a definitive survival prediction.
Last updated:
This page uses a site-defined composite worksheet that combines disease setting, ECOG status, PSA, Gleason or grade-group pattern, metastatic burden, and selected laboratory abnormalities into broad prognostic bands. CHAARTED high-volume criteria and related trial concepts are used as contextual anchors, but the page does not reproduce a single validated survival calculator.
The result is therefore prognosis context only. Real treatment and survival discussions depend on imaging, genomic findings, treatment response, prior systemic therapy, castration status, symptoms, and specialist review.
Metastatic castration-sensitive prostate cancer (mCSPC) refers to disease that still responds to androgen deprivation therapy (ADT). Metastatic castration-resistant prostate cancer (mCRPC) is disease that progresses despite castrate testosterone levels (< 50 ng/dL). The transition to CRPC represents a critical inflection point in the disease trajectory, with shorter expected survival and different treatment options.
The CHAARTED trial defined high-volume disease as having ≥ 4 bone metastases with at least 1 beyond the axial skeleton (spine/pelvis), OR having visceral metastases (liver, lung, brain, etc.). High-volume disease has significantly worse prognosis and benefits most from upfront combination therapy (ADT + docetaxel ± novel hormone agent) compared to ADT alone.
Higher Gleason scores (grade groups 4-5, Gleason 8-10) indicate more aggressive tumor biology with poorer differentiation and higher proliferation rates. These cancers are more likely to develop castration resistance quickly and metastasize to visceral organs. Gleason 9-10 disease carries the worst prognosis and often requires the most aggressive combination treatment.
Triplet therapy (ADT + docetaxel + novel hormone agent like abiraterone) has shown benefit particularly in high-volume/high-risk mCSPC (PEACE-1, ARASENS). However, it carries increased toxicity. Low-volume disease may be adequately treated with ADT + a novel hormone agent alone. Treatment selection should balance expected benefit against toxicity, considering patient fitness, comorbidities, and preferences.
Homologous recombination repair (HRR) gene testing (BRCA1, BRCA2, ATM, PALB2, etc.) is now standard in mCRPC. BRCA1/2 mutations predict response to PARP inhibitors (olaparib, rucaparib). Microsatellite instability (MSI-H) may predict response to pembrolizumab. Tumor mutational burden and other biomarkers are being studied. These do not replace clinical prognostic factors but add precision to treatment selection.
ALP reflects osteoblastic bone activity and is elevated when prostate cancer metastasizes to bone. Higher ALP levels correlate with greater bone tumor burden and shorter survival. ALP > 200 U/L is an independent adverse prognostic factor across multiple models (Halabi, Armstrong). It can also serve as a treatment response marker — declining ALP often indicates responding disease.